Human TRAIL R2/TNFRSF10B Antibody

Catalog # Availability Size / Price Qty
MAB631-SP
MAB631-500
MAB631-100
Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells.
4 Images
Product Details
Citations (17)
FAQs
Supplemental Products
Reviews

Human TRAIL R2/TNFRSF10B Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R2/TNFRSF10B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or rhDcR3.
Source
Monoclonal Mouse IgG1 Clone # 71903
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
Met1-Glu182
Accession # CAG46696
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Agonist Activity
2-12 ng/mL
See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Agonist Activity Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells. View Larger

Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells. Human TRAIL R2/TNFRSF10B Monoclonal Antibody induces apoptosis of the Jurkat human acute T cell leukemia cell line in a dose-dependent manner, as measured by Resazurin (Catalog # AR002). The ED50 for this effect is typically 2-12 ng/mL.

Western Blot Detection of Human TRAILR2/TNFRSF10B by Western Blot View Larger

Detection of Human TRAILR2/TNFRSF10B by Western Blot Cleavage of FRET probe is indicative of caspase activation.Cells were treated with (A) 0–300 ng/ml TRAIL for 2.5 hours or (B) 0–50 µg/ml anti-DR5 antibody for 20 h. The resultant cells were analyzed by western blotting using antibodies specific to caspase 3 (C3), caspase 8 (C8), and CFP/YFP. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.

Functional Detection of Human TRAILR2/TNFRSF10B by Functional View Larger

Detection of Human TRAILR2/TNFRSF10B by Functional MB231_CFP-YFP cells retain sensitivity to TRAIL and anti-DR5 antibody.(A) Parental MB231 (filled black) and MB231_CFP-YFP (open clear) cells were treated with TRAIL (0–100 ng/ml) for 2.5 h or anti-DR5 antibody (0–200 µg/ml) for 20 h, at the indicated concentrations. Cell viability was determined by MTT assay. (B) Cells were treated as in A and analyzed for apoptosis by flow cytometry after staining with Annexin-V-APC and propidium iodide (PI). p-values were determined using a Student’s t-test. EC50 values were determined using nonlinear curve fitting as described in the Materials and Methods section. For each EC50 value, 95% confidence intervals reflecting the statistical accuracy are reported in Table 1. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.

Functional Detection of Human TRAILR2/TNFRSF10B by Functional View Larger

Detection of Human TRAILR2/TNFRSF10B by Functional Cell-based FRET biosensor provides a quantifiable response to treatments of death receptor targeted cancer therapies.MB231_CFP-YFP cells were treated with (A) 0–300 ng/ml TRAIL for 2.5 h and (B) 0–100 µg/ml anti-DR5 antibody for 20 h. FRET was calculated and is represented using bar graphs on the left side of the panel. EC50 values were determined by nonlinear curve fitting to normalized FRET values plotted against the log values of TRAIL and anti-DR5 antibody concentration in molar (right side of the panel). (C) Confocal microscopy images showing changes in FRET in MB231_CFP-YFP cells treated with 0–25 ng/ml TRAIL for 2.5 h. A pronounced shift from YFP acceptor emission (yellow) to CFP donor emission (cyan) can be observed for cells treated with increasing concentration of TRAIL, with an excitation setting = 458 nm. Statistical analysis was performed as in Fig. 1 and 2. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAIL R2/TNFRSF10B

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References
  1. Chaudhary, P.M. et al. (1997) Immunity 7:821.
  2. Walczak, H. et al. (1997) EMBO J. 16:5386.
  3. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 2
Entrez Gene IDs
8795 (Human); 21933 (Mouse)
Alternate Names
CD262 antigen; CD262; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9

Product Datasheets

You must select a language.

x

Citations for Human TRAIL R2/TNFRSF10B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma
    Authors: K.L. Phillips, N. Wright, E. McDermott, N.A. Cross
    Biochemical and Biophysical Research Communications
  2. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization
    Authors: Yoshihiro Suzuki-Karasaki, Kyoko Fujiwara, Kosuke Saito, Miki Suzuki-Karasaki, Toyoko Ochiai, Masayoshi Soma
    Oncotarget
  3. Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics
    Authors: Asuka Onoe‑Takahashi, Manami Suzuki‑Karasaki, Miki Suzuki‑Karasaki, Toyoko Ochiai, Yoshihiro Suzuki‑Karasaki
    International Journal of Oncology
  4. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling
    Authors: Liqiang Pan, Tian-Min Fu, Wenbin Zhao, Linlin Zhao, Wen Chen, Chixiao Qiu et al.
    Cell
  5. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.
    Authors: Kang Z, Goldstein S, Yu Y, Meltzer P, Loeb D, Cao L
    Br J Cancer, 2015-08-20;113(6):894-901.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  6. The use of a stably expressed FRET biosensor for determining the potency of cancer drugs.
    Authors: Bozza, William, Di, Xu, Takeda, Kazuyo, Rivera Rosado, Leslie A, Pariser, Sarah, Zhang, Baolin
    PLoS ONE, 2014-09-04;9(9):e107010.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  7. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.
    Authors: Meng X, Koh B, Zhang J, Flatten K, Schneider P, Billadeau D, Hess A, Smith B, Karp J, Kaufmann S
    J Biol Chem, 2014-07-25;289(30):20543-58.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  8. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
    Authors: Matte I, Lane D, Boivin M, Rancourt C, Piche A
    BMC Cancer, 2014-04-01;14(0):234.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  9. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
    Authors: Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L
    Clin Cancer Res, 2011-03-08;17(10):3181-92.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  10. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009-08-18;114(18):3854-63.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  11. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
    Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  12. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
    Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
    Oncogene, 2003-03-20;22(11):1653-62.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  13. Tracing cellular heterogeneity in pooled genetic screens via multi-level barcoding
    Authors: Michael Boettcher, Sergio Covarrubias, Anne Biton, James Blau, Haopeng Wang, Noah Zaitlen et al.
    BMC Genomics
  14. Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function
    Authors: Andrew K. Lewis, Christopher C. Valley, Stephen L. Peery, Benjamin Brummel, Anthony R. Braun, Christine B. Karim et al.
    Journal of Molecular Biology
  15. Induction of pro-apoptotic antibodies to triple negative breast cancer by vaccination with TRAIL death receptor DR5 DNA
    Authors: Marie P. Piechocki, Gen Sheng Wu, Richard F. Jones, Jennifer B. Jacob, Heather Gibson, Stephen P. Ethier et al.
    International Journal of Cancer
  16. The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation
    Authors: Amr M. El Zawily, Behzad M. Toosi, Tanya Freywald, Vijaya V. Indukuri, Franco J. Vizeacoumar, Scot C. Leary et al.
    Oncotarget
  17. Disrupting mitochondrial Ca2+ homeostasis causes tumor-selective TRAIL sensitization through mitochondrial network abnormalities
    Authors: Yohei Ohshima, Natsuhiko Takata, Miki Suzuki-Karasaki, Yukihiro Yoshida, Yasuaki Tokuhashi, Yoshihiro Suzuki-Karasaki
    International Journal of Oncology

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAIL R2/TNFRSF10B Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL R2/TNFRSF10B Antibody and earn rewards!

Have you used Human TRAIL R2/TNFRSF10B Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review